Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...

This year’s Tour departs from Barcelona in July and while Healy says he hasn’t looked at the 2026 route yet, he does dream ...

Ever wondered if Roche Holding is trading at a bargain or a premium? You are not alone, especially with all the chatter about big pharma valuations these days. The stock has shown some real momentum, ...

Conducted over more than 96 weeks, the first trial "significantly reduced the annualized relapse rate (ARR) compared to teriflunomide," an RMS drug developed by Sanofi and currently available as a ...

Wondering if Roche Holding might be a hidden gem in today’s market? You’re not alone, as many investors are taking a closer look at what makes this pharmaceutical giant’s stock interesting right now.

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market for weight-loss medicines. The drug, known as CT-388, ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Roche ROG1.88%increase; green up pointing triangle Holding said it agreed to buy 89bio for up to $3.5 billion, seeking to bolster its drug pipeline by adding an experimental treatment for a liver ...

Roche's acquisition of 89bio aims to strengthen its portfolio in cardiovascular, renal, and metabolic diseases, focusing on obesity-related comorbidities like MASH. The merger agreement includes a $14 ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the drug in preclinical-stage patients at elevated risk of cognitive decline. The ...

Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for multiple sclerosis, eye disease and cancer. The Swiss drugmaker has discussed ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning the President Trump administration for an exemption. Roche is trying to ...